Why the study?
Intravenous angiotensin II was registered in the Czech Republic in 2023, prompting the need to summarize scientific evidence and provide an interdisciplinary expert statement on its use in intensive care.
This document provides an interdisciplinary consensus statement on the use of intravenous angiotensin II for patients with refractory vasoplegic shock in intensive care units in the Czech Republic.
Panel endorses angiotensin II for refractory vasoplegic shock; leaves open need for RCTs to confirm efficacy and safety.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Balík et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: